$8.63
+0.51
(+6.28%)▲
Insights on Immunitybio Inc.
Revenue is down for the last 2 quarters, 139.0K → 40.0K (in $), with an average decrease of 71.2% per quarter
Netprofit is up for the last 2 quarters, -233.39M → -134.10M (in $), with an average increase of 74.0% per quarter
In the last 3 years, Novo Nordisk A/s has given 224.7% return, outperforming this stock by 271.0%
6.84%
Downside
Day's Volatility :9.31%
Upside
2.65%
85.52%
Downside
52 Weeks Volatility :88.13%
Upside
18.04%
Period | Immunitybio Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 91.96% | -0.4% | 0.0% |
6 Months | 136.05% | 12.3% | 0.0% |
1 Year | 152.17% | 8.6% | 1.6% |
3 Years | -43.85% | 16.3% | -20.5% |
Market Capitalization | 5.5B |
Book Value | - $0.87 |
Earnings Per Share (EPS) | -1.15 |
Wall Street Target Price | 7.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -60792.8% |
Return On Assets TTM | -52.11% |
Return On Equity TTM | 0.0% |
Revenue TTM | 622.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 90.4% |
Gross Profit TTM | 240.0K |
EBITDA | -342.9M |
Diluted Eps TTM | -1.15 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.74 |
EPS Estimate Next Year | -0.52 |
EPS Estimate Current Quarter | -0.16 |
EPS Estimate Next Quarter | -0.17 |
What analysts predicted
Downside of 13.09%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 47.0K | ↑ 4.44% |
Net Income | -96.2M | ↓ 0.2% |
Net Profit Margin | -204.7K% | ↑ 9537.16% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.2M | ↑ 4585.11% |
Net Income | -160.2M | ↑ 66.44% |
Net Profit Margin | -7.3K% | ↑ 197462.87% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 605.0K | ↓ 72.52% |
Net Income | -224.2M | ↑ 39.98% |
Net Profit Margin | -37.1K% | ↓ 29782.4% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 934.0K | ↑ 54.38% |
Net Income | -349.8M | ↑ 56.05% |
Net Profit Margin | -37.5K% | ↓ 401.26% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 240.0K | ↓ 74.3% |
Net Income | -417.3M | ↑ 19.29% |
Net Profit Margin | -173.9K% | ↓ 136426.37% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 622.0K | ↑ 159.17% |
Net Income | -583.2M | ↑ 39.75% |
Net Profit Margin | -93.8K% | ↑ 80121.92% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 73.0K | ↓ 38.14% |
Net Income | -108.3M | ↓ 2.35% |
Net Profit Margin | -148.4K% | ↓ 54376.53% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 360.0K | ↑ 393.15% |
Net Income | -151.2M | ↑ 39.54% |
Net Profit Margin | -42.0K% | ↑ 106402.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 41.0K | ↓ 88.61% |
Net Income | -137.9M | ↓ 8.79% |
Net Profit Margin | -336.3K% | ↓ 294300.8% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 82.0K | ↑ 100.0% |
Net Income | -95.6M | ↓ 30.68% |
Net Profit Margin | -116.6K% | ↑ 219726.83% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 139.0K | ↑ 69.51% |
Net Income | -233.4M | ↑ 144.18% |
Net Profit Margin | -167.9K% | ↓ 51344.5% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 40.0K | ↓ 71.22% |
Net Income | -134.1M | ↓ 42.54% |
Net Profit Margin | -335.3K% | ↓ 167364.59% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 182.0M | ↓ 27.35% |
Total Liabilities | 35.9M | ↑ 13.76% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 143.1M | ↓ 21.34% |
Total Liabilities | 22.4M | ↓ 37.56% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 221.4M | ↑ 54.68% |
Total Liabilities | 339.9M | ↑ 1414.31% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 468.9M | ↑ 111.81% |
Total Liabilities | 712.8M | ↑ 109.73% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 362.4M | ↓ 22.72% |
Total Liabilities | 812.2M | ↑ 13.94% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 504.5M | ↑ 39.21% |
Total Liabilities | 1.1B | ↑ 34.26% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 362.4M | ↑ 2.67% |
Total Liabilities | 812.2M | ↑ 3.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 343.4M | ↓ 5.23% |
Total Liabilities | 875.1M | ↑ 7.75% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 291.2M | ↓ 15.19% |
Total Liabilities | 936.4M | ↑ 7.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 432.4M | ↑ 48.48% |
Total Liabilities | 843.1M | ↓ 9.97% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 504.5M | ↑ 16.66% |
Total Liabilities | 1.1B | ↑ 29.34% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 400.7M | ↓ 20.57% |
Total Liabilities | 1.1B | ↑ 0.12% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -63.4M | ↑ 29.93% |
Investing Cash Flow | 25.7M | ↓ 74.2% |
Financing Cash Flow | -771.0K | ↓ 97.8% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -152.1M | ↑ 139.99% |
Investing Cash Flow | -6.3M | ↓ 124.59% |
Financing Cash Flow | 114.3M | ↓ 14922.18% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -171.7M | ↑ 12.9% |
Investing Cash Flow | -1.4M | ↓ 78.29% |
Financing Cash Flow | 150.7M | ↑ 31.85% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -274.4M | ↑ 59.8% |
Investing Cash Flow | -84.9M | ↑ 6091.54% |
Financing Cash Flow | 505.4M | ↑ 235.45% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -337.5M | ↑ 22.99% |
Investing Cash Flow | 27.3M | ↓ 132.16% |
Financing Cash Flow | 233.6M | ↓ 53.78% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -90.7M | ↑ 12.56% |
Investing Cash Flow | -18.9M | ↑ 1517.64% |
Financing Cash Flow | 109.9M | ↓ 11.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -84.3M | ↓ 7.07% |
Investing Cash Flow | -8.5M | ↓ 55.1% |
Financing Cash Flow | 76.9M | ↓ 30.06% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -79.8M | ↓ 5.38% |
Investing Cash Flow | -8.6M | ↑ 1.41% |
Financing Cash Flow | 43.4M | ↓ 43.54% |
Sell
Neutral
Buy
Immunitybio Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Immunitybio Inc. | 54.96% | 136.05% | 152.17% | -43.85% | -75.01% |
Moderna, Inc. | 12.95% | 67.08% | -9.94% | -21.73% | 380.19% |
Regeneron Pharmaceuticals, Inc. | 8.37% | 22.23% | 29.67% | 88.29% | 219.12% |
Novo Nordisk A/s | 3.65% | 27.43% | 51.59% | 225.57% | 442.2% |
Vertex Pharmaceuticals Incorporated | 8.2% | 14.28% | 23.31% | 94.75% | 157.88% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Immunitybio Inc. | NA | NA | NA | -0.74 | 0.0 | -0.52 | NA | -0.87 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.67 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.57 | 28.57 | 1.46 | 44.24 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.83 | 44.83 | 2.4 | 3.4 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 27.17 | 27.17 | 0.53 | 16.94 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Immunitybio Inc. | Buy | $5.5B | -75.01% | NA | 0.0% |
Moderna, Inc. | Buy | $47.0B | 380.19% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $106.7B | 219.12% | 28.57 | 29.45% |
Novo Nordisk A/s | Buy | $573.2B | 442.2% | 44.83 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $108.1B | 157.88% | 27.17 | 39.46% |
Vanguard Group Inc
BlackRock Inc
State Street Corporation
Geode Capital Management, LLC
Goldman Sachs Group Inc
Credit Suisse First Boston (CSFB)
Immunitybio Inc.’s price-to-earnings ratio stands at None
Read Moreimmunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.
Organization | Immunitybio Inc. |
Employees | 628 |
CEO | Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. |
Industry | Healthcare |